Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
Since the discovery of induced pluripotent stem cell (iPSC) technology 15 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.
As we enter 2021, Cynata Therapeutics is initiating a historic trial that will utilize its iPSC-derived product, CYP-004, in 440 patients with osteoarthritis (OA). This will be the world’s first Phase 3 trial to administer an iPSC-derived cellular therapeutic to human patients and the largest one ever. [Read more…]
Induced pluripotent stem cells (iPS cells) can be made by reprogramming mature adult cells back into an embryonic-like state. Derived from skin or blood cells, iPS cells are not controversial, because they are made from adult cells. As pluripotent stem cells, they can give rise to all of the tissues that form the human body. [Read more…]
Numerous induced pluripotent stem cell (iPSC) derived therapeutics are now being studied in preclinical and clinical trials to investigate their potential to produce functional cells capable of replacing damaged or dysfunctional tissues.
It is important to note that the early clinical trials of iPSCs—and the majority of them today—do not involve the transplant of iPSCs into humans. Rather, they involve the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest. [Read more…]
TUCSON, Ariz. and PALO ALTO, Calif., Dec. 16, 2020 — Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo Alto-based biotech startup developing, mass-manufacturing, and commercializing Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs), announced a service agreement to advance cell therapy for heart failure. Under the agreement, I Peace will generate and supply GMP-grade induced pluripotent stem cells (iPSCs) and related services to Avery Therapeutics. Avery Therapeutics will use the iPSCs to derive cells used in the manufacturing of MyCardia™. [Read more…]